SCOPE 2023: Beat AML Master Trial Successes

While steady progress has been made in recent years, CROs and sponsors still have decisions to make on which solutions are best for them.

It is unrealistic to include infinite adaptations in an IRT system, thus identifying the optimal level of adaptations requires examination of the study’s characteristics and planning phase considerations.

Perceived barriers of DCTs can be quickly overcome to ensure their viability in clinical research.

DIA 2023 panel discussed personal experiences in clinical trials and offer suggestions for improvements to focus on the participants.

Session at DIA discusses the International Medical Device Regulators Forum (IMDRF), its importance and how harmonization could be improved.

CDER and CBER leaders update initiatives in the rare disease space within the past year.